Julian Rydzek

1.2k total citations · 1 hit paper
7 papers, 850 citations indexed

About

Julian Rydzek is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Julian Rydzek has authored 7 papers receiving a total of 850 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Immunology and 3 papers in Molecular Biology. Recurrent topics in Julian Rydzek's work include CAR-T cell therapy research (7 papers), Virus-based gene therapy research (2 papers) and Immune Cell Function and Interaction (2 papers). Julian Rydzek is often cited by papers focused on CAR-T cell therapy research (7 papers), Virus-based gene therapy research (2 papers) and Immune Cell Function and Interaction (2 papers). Julian Rydzek collaborates with scholars based in Germany, Austria and United States. Julian Rydzek's co-authors include Michael Hudecek, Hermann Einsele, Thomas Nerreter, Theodoros Giavridis, Michel Sadelain, Katrin Mestermann, Silke Frenz, Justus Weber, Andreas Mades and Martin Schreder and has published in prestigious journals such as Blood, Nature Immunology and Science Translational Medicine.

In The Last Decade

Julian Rydzek

7 papers receiving 843 citations

Hit Papers

The tyrosine kinase inhibitor dasatinib acts as a pharmac... 2019 2026 2021 2023 2019 100 200 300

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julian Rydzek Germany 5 741 300 287 265 205 7 850
Brandon Ballard United States 10 847 1.1× 326 1.1× 311 1.1× 226 0.9× 259 1.3× 16 1.0k
Simon Thomas United Kingdom 10 677 0.9× 279 0.9× 201 0.7× 266 1.0× 215 1.0× 28 773
Namiko Okuyama Japan 6 747 1.0× 285 0.9× 467 1.6× 208 0.8× 163 0.8× 9 945
Margot J. Pont United States 13 600 0.8× 326 1.1× 235 0.8× 167 0.6× 118 0.6× 27 798
Annalisa Cabriolu United States 6 787 1.1× 351 1.2× 323 1.1× 323 1.2× 223 1.1× 9 974
Sanfang Tu China 16 582 0.8× 297 1.0× 201 0.7× 144 0.5× 154 0.8× 52 858
Caroline Arber United States 16 504 0.7× 235 0.8× 343 1.2× 132 0.5× 164 0.8× 30 762
Brigitte Neuber Germany 16 529 0.7× 260 0.9× 229 0.8× 140 0.5× 169 0.8× 42 698
Yinmeng Yang United States 9 662 0.9× 338 1.1× 325 1.1× 174 0.7× 210 1.0× 18 877
Diogo Gomes‐Silva United States 6 759 1.0× 329 1.1× 274 1.0× 180 0.7× 312 1.5× 9 857

Countries citing papers authored by Julian Rydzek

Since Specialization
Citations

This map shows the geographic impact of Julian Rydzek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julian Rydzek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julian Rydzek more than expected).

Fields of papers citing papers by Julian Rydzek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julian Rydzek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julian Rydzek. The network helps show where Julian Rydzek may publish in the future.

Co-authorship network of co-authors of Julian Rydzek

This figure shows the co-authorship network connecting the top 25 collaborators of Julian Rydzek. A scholar is included among the top collaborators of Julian Rydzek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julian Rydzek. Julian Rydzek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Gudipati, Venugopal, Julian Rydzek, Elisabeth Lobner, et al.. (2020). Inefficient CAR-proximal signaling blunts antigen sensitivity. Nature Immunology. 21(8). 848–856. 92 indexed citations
2.
Mestermann, Katrin, Theodoros Giavridis, Justus Weber, et al.. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine. 11(499). 379 indexed citations breakdown →
3.
Mestermann, Katrin, et al.. (2019). Abstract A037: A novel pharmacologic “ON/OFF” switch to modulate CAR-T-cell function in vitro and in vivo. Cancer Immunology Research. 7(2_Supplement). A037–A037. 1 indexed citations
4.
García‐Cadenas, Irene, Thomas Nerreter, Simone Thomas, et al.. (2018). CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 32(5). 1168–1179. 153 indexed citations
5.
Rydzek, Julian, Thomas Nerreter, Haiyong Peng, et al.. (2018). Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform. Molecular Therapy. 27(2). 287–299. 40 indexed citations
6.
Mestermann, Katrin, Julian Rydzek, Silke Frenz, et al.. (2018). A Novel Pharmacologic 'Remote Control' to Steer CAR-T Cell Function In Vivo. Blood. 132(Supplement 1). 2055–2055. 1 indexed citations
7.
Gogishvili, Tea, Sophia Danhof, Sabrina Prommersberger, et al.. (2017). SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood. 130(26). 2838–2847. 184 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026